DEPARTMENT OF HEALTH AND HUMAN SERVICES				
FOOD AND DRUG ADMINISTRATION				
DISTRICT OFFICE ADDRESS AND PHONE NUMBER		DATE(S) OF INSPECTION		
60 Eighth Street NE		07/31/2017 - 08/04/2017		
Atlanta, GA 30309 404-253-1161		FEI NUMBER		
		3012184662		
Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED				
TO: Douglas R. Yoch, Owner / Pharmacist in Charge				
IRM NAME STREET ADDRESS				
Stanley Specialty Pharmacy Compounding and Wellness Center	3120 Latrobe Dr. Suite	3120 Latrobe Dr. Suite 200		
CITY, STATE AND ZIP CODE	TYPE OF ESTABLISHMENT INSPECTED			
Charlotte, NC 28211 Producer of sterile and non-sterile drugs				
THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.				
OBSERVATION 1				
Environmental monitoring was not performed in your aseptic processing areas.				
Specifically,				
(b) (4) samples collected within the ISO 8 $^{(b)}$ (4) and (b) (4) areas, ISO 7 (b) (4)room, and (b) (4) ISO 5				
laminar flow hoods, are only collected on a (b) (4) basis after cleaning.				
OBSERVATION 2				
Disinfecting agents and cleaning pads or wipes used in the ISO 5 aseptic processing areas are not sterile.				
Specifically, Your firm uses a non-sterile, non-sporocidal disinfectant (b) (4) with non-sterile wipes for all surfaces within the ISO classified areas, including in the ISO 5 laminar flow hoods where aseptic processes are conducted.				
OBSERVATION 3				
There is insufficient data to support the percentage of preservative used to ensure anti-microbial effectiveness in multi-dose stock solutions which are used to formulate finished product.				
Add Continuation Page				
EMPLOYEE(S) SIGNATURE	EMPLOYEE(S) NAME AND TITLE	E (Print or Type)	DATE ISSUED	
REVERSE OF THIS PAGE Bonita Choster	Seneca Toms, Investigator Bonita Chester, Investigator		08/04/2017	
FORM FDA 483 (9/08) PREVIOUS EDITION OBSOLETE	SPECTIONAL OBSERVA	TIONS	Page 1 of 1	